Abciximab (c7E3 fab, ReoPro) with reduced heparin dosing during coronary intervention: Final results of the EPILOG trial
Publication
, Journal Article
Lincoff, AM; Tcheng, JE; Califf, RM; Cabot, CF; Miller, DP; Booth, JE; Montague, EA; Anderson, KM; Topol, EJ
Published in: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
February 1, 1997
Duke Scholars
Published In
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
ISSN
0735-1097
Publication Date
February 1, 1997
Volume
29
Issue
2
Start / End Page
7396 / 7396
Publisher
ELSEVIER SCIENCE INC
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Lincoff, A. M., Tcheng, J. E., Califf, R. M., Cabot, C. F., Miller, D. P., Booth, J. E., … Topol, E. J. (1997). Abciximab (c7E3 fab, ReoPro) with reduced heparin dosing during coronary intervention: Final results of the EPILOG trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 29(2), 7396–7396.
Lincoff, A. M., J. E. Tcheng, R. M. Califf, C. F. Cabot, D. P. Miller, J. E. Booth, E. A. Montague, K. M. Anderson, and E. J. Topol. “Abciximab (c7E3 fab, ReoPro) with reduced heparin dosing during coronary intervention: Final results of the EPILOG trial.” JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 29, no. 2 (February 1, 1997): 7396–7396.
Lincoff AM, Tcheng JE, Califf RM, Cabot CF, Miller DP, Booth JE, et al. Abciximab (c7E3 fab, ReoPro) with reduced heparin dosing during coronary intervention: Final results of the EPILOG trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 1997 Feb 1;29(2):7396–7396.
Lincoff, A. M., et al. “Abciximab (c7E3 fab, ReoPro) with reduced heparin dosing during coronary intervention: Final results of the EPILOG trial.” JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 29, no. 2, ELSEVIER SCIENCE INC, Feb. 1997, pp. 7396–7396.
Lincoff AM, Tcheng JE, Califf RM, Cabot CF, Miller DP, Booth JE, Montague EA, Anderson KM, Topol EJ. Abciximab (c7E3 fab, ReoPro) with reduced heparin dosing during coronary intervention: Final results of the EPILOG trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC; 1997 Feb 1;29(2):7396–7396.
Published In
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
ISSN
0735-1097
Publication Date
February 1, 1997
Volume
29
Issue
2
Start / End Page
7396 / 7396
Publisher
ELSEVIER SCIENCE INC
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology